Latest Conference Articles

New cell therapy drug makes treatment of corneal endothelial disease more accessible.

Hear what Sumayya Ahmad, MD, and Jai G. Parekh, MD, MBA, have to say about current concepts for the management and treatment of dry eye.

Jay Duker, MD, discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.

At AAO 2021, Aerie Pharmaceuticals presented the results of their phase 2b clinical trial of AR-15512, a triple 8 antagonist, for the treatment of dry eye.

Mohamed Abou Shousha, MD, PhD, discusses Heru’s wearable AI-powered diagnostic devices at AAO 2021.

Verana Health showcases the VeraQ quality measures dashboard for the IRIS registry report at AAO 2021.

Save the dates for this virtual interactive conference featuring top US ophthalmologists

A brief overview of the plethora of findings presented at the 2021 American Academy of Ophthalmology meeting held November 12-15 in New Orleans, LA.

Mark Wieland, MD, explores how Port Delivery System with ranibizumab provides drug delivery over an extended period.

Ines Lains, MD, PhD, explores how mechanisms of AMD progression currently remain poorly understood and the tools to predict and halt progression are limited.

Sunir J. Garg, MD, speaks on the influence of COVID-19 universal face masking on the risk of endophthalmitis following intravitreal anti-VEGF injections.

Cathleen McCabe, MD, discusses VUITY, the first and only FDA-approved eye drop to treat age-related blurry near vision, and how it provides opportunities for patients looking for spectacle independence.

ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.

Nathan Hall, BS, MS, presents research on how epidemiologic analysis of malignant ocular surface tumors found significant differences in geographic prevalence rates in the United States.

Roger A. Goldberg, MD, MBA, notes how small misalignments in the plunger can lead to possible overdosing.

Ajay Kuriyan, MD, discusses fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular edema in clinical trial setting.

Denise Freitas, MD, reports on ocular findings in infants with congenital Zika virus syndrome that were similar among the affected infants and occurred frequently.

Felipe Medeiros, MD, presents results from a phase 3 clinical extension study of the bimatoprost implant that found patients’ IOP was lowered and stayed low with no additional treatment or changes in their visual fiends.

Gareth Lema, MD, PhD, spotlights a treatment could provide benefits for patients with central retinal artery occlusion.

Bausch + Lomb's Yolande Barnard, shares an update on the FDA approval of XIPERE for the treatment of macular edema associated with uveitis.

Dilsher Dhoot, MD, reports results of the KESTREL and KITE trials, in which brolucizumab was compared with aflibercept for treating diabetic macular edema.

The Academy's annual meeting set for November 12 to 15 in New Orleans.

Ankur Shah, MD, discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.

David Boyer, MD, reports on the use of pegcetacoplan to treat geographic atrophy when administered monthly or every-other-month regimens in the phase 3 DERBY and OAKS studies.

Richard B. Rosen, MD, DSc(Hon), reports on the capabilities of using clinical OCT for imaging and measuring macular surface macrophage cells during the 2021 ASRS annual meeting.

Sunir Garg, MD, reports on the risk of presumed infectious endophthalmitis following administration of anti-VEFG injections in correlation with universal masking.

Yoshihiro Yonekawa, MD, reports on the findings of an investigation looking at the prevalence of endophthalmitis following minimally invasive glaucoma surgery.

Alcon's Paul Hallen offers a look at the highlights from the 2021 ASRS annual meeting's OIS panel as well as the company's latest innovations.